777P A prospective, single-arm, open-label study of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer

Abstract

Cervical cancer is ranked the fourth most common female malignancy worldwide. The prognosis with metastatic or recurrent cervical cancer remains poor, the objective response rate (ORR) of different second chemotherapy treatments ranges from 4.5% to 31.0%. Camrelizumab is an immune checkpoint inhibitor, apatinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, albumin-bound paclitaxel (nab-paclitaxel) is a second-line-recommended chemotherapy in advanced cervical cancer.